减轻耳的负担:为探索有效的药理学策略进行叙事审查
Seung Ho Kim1, Ikhee Kim1, Hantai Kim1
1Department of Otorhinolaryngology-Head and Neck Surgery, Konyang University College of Medicine, Daejeon, KOR.
Cureus
|March 27, 2024
概括
药物治疗为慢性主观耳提供了有限的缓解,但可以帮助管理同时出现的抑郁或焦虑. 一些耳类型可能受益于特定的药物,增强对TRT和CBT等疗法的坚持.
科学领域:
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 神经学 神经学
- 精神病学是一个精神病学.
背景情况:
- 耳显著影响生活质量,许多患者寻求医疗救济.
- 目前的主要治疗方法,如耳复习疗法 (TRT) 和认知行为疗法 (CBT),需要大量的患者承诺.
- 对于更简单,以药物为基础的解决方案的渴望在声患者中持续存在.
研究的目的:
- 探索药理干预措施在管理耳的作用和有效性.
- 为了区分慢性主观耳与专业耳形式的药物效用.
- 评估药物的影响,包括安慰剂效应,对患者遵守既定疗法.
主要方法:
- 审查当前的治疗指南和 tinnitus 药物治疗的临床证据.
- 对特定声亚型 (例如,打字机声) 药物使用的分析.
- 考虑辅助药物治疗并发性心理疾病 (抑郁症,焦虑症).
- 评估安慰剂效应对耳治疗满意度的影响.
主要成果:
- 药物不是慢性主观耳的第一线治疗方法.
- 抗抑郁药和抗焦虑药可以缓解 tinnitus 与抑郁症或焦虑症并发症时的症状.
- 某些专门的耳类型,与慢性主观耳不同,可能会对特定的药物产生反应.
- 内甲松的疗效有限,但安慰剂反应显著.
- 从药物中获得主观缓解可以改善TRT和CBT的坚持.
结论:
- 药理干预在声管理中起到次要或辅助作用.
- 药物的价值在于管理并发病症,并可能改善对初级疗法的坚持.
- 安慰剂效应是显著的,并有助于患者报告的满意度和治疗遵守.
相关概念视频
Management of Insomnia
244
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
244
Analgesia and Pain Management
614
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
614
Sedatives and Hypnotics Drugs: Miscellaneous Agents
171
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
171
Tonsillitis II: Management
110
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
110
Antidepressant Drugs: MAOIs and Other Agents
228
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
228
Desensitization and Tachyphylaxis
1.7K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.7K


